nach oben

Current Pain and Headache Reports

Erschienen in:

01.02.2018 | Other Pain (A Kaye and N Vadivelu, Section Editors)

Intrathecal Drug Delivery and Spinal Cord Stimulation for the Treatment of Cancer Pain

verfasst von: Fangfang Xing, R. Jason Yong, Alan David Kaye, Richard D. Urman

Erschienen in: Current Pain and Headache Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of the present investigation is to summarize the body and quality of evidence including the most recent studies in support of intrathecal drug delivery systems and spinal cord stimulation for the treatment of cancer-related pain.

Recent Findings

In the past 3 years, a number of prospective studies have been published supporting intrathecal drug delivery systems for cancer pain. Additional investigation with adjuvants to morphine-based analgesia including dexmedetomidine and ziconotide support drug-induced benefits of patient-controlled intrathecal analgesia. A study has also been recently published regarding cost-savings for intrathecal drug delivery system compared to pharmacologic management, but an analysis in the Ontario, Canada healthcare system projects additional financial costs. Finally, the Polyanalgesic Consensus Committee has updated its recommendations regarding clinical guidelines for intrathecal drug delivery systems to include new information on dosing, trialing, safety, and systemic opioid reduction. There is still a paucity of clinical evidence for spinal cord stimulation in the treatment of cancer pain. There are new intrathecal drugs under investigation including various conopeptides and AYX1.

Summary

Large, prospective, modern, randomized controlled studies are still needed to support the use of both intrathecal drug delivery systems as well as spinal cord stimulation for cancer pain populations. There are multiple prospective and small randomized controlled studies that highlight a potential promising future for these interventional modalities. Related to the challenge and urgency of cancer pain, the pain practitioner community is moving toward a multimodal approach that includes discussions regarding the role of intrathecal therapies and spinal cord stimulation to the individualized treatment of patients.

Valeberg BT, Rustoen T, Bjordal K, Hanestad BR, Paul S, Miaskowski C. Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. Eur J Pain. 2008;12(5):582–90. https://doi.org/10.1016/j.ejpain.2007.09.004.CrossRefPubMed

• Candido KD, Kusper TM, Knezevic NN. New cancer pain treatment options. Curr Pain Headache Rep. 2017;21(2):12. Review of shifting paradigms in cancer pain treatment as well as interventional techniques available for clinical use. https://doi.org/10.1007/s11916-017-0613-0.CrossRefPubMed

• Sindt JE, Brogan SE. Interventional treatments of cancer pain. Anesthesiol Clin. 2016;34(2):317–39. Review of practical considerations in the techniques used for interventional cancer pain treatment. https://doi.org/10.1016/j.anclin.2016.01.004.CrossRefPubMed

Stearns L, Boortz-Marx R, Du Pen S, Friehs G, Gordon M, Halyard M, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3(6):399–408.PubMed

Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979;50(2):149–51. https://doi.org/10.1097/00000542-197902000-00013.CrossRefPubMed

Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56(8):516–20.PubMed

• Abrecht CR, Greenberg P, Song E, Urman RD, Rathmell JP. A contemporary medicolegal analysis of implanted devices for chronic pain management. Anesth Analg. 2017;124(4):1304–10. Analysis of closed malpractice claims related to spinal cord stimulators and intrathecal drug delivery systems. https://doi.org/10.1213/ANE.0000000000001702.CrossRefPubMed

Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65–76. https://doi.org/10.1016/0304-3959(95)00017-M.CrossRefPubMed

Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch SJ 3rd, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5(3):239–47. https://doi.org/10.1111/j.1526-4637.2004.04037.x.CrossRefPubMed

10.

• Deer TR, Caraway DL, Wallace MS. A definition of refractory pain to help determine suitability for device implantation. Neuromodulation. 2014;17(8):711–5. Review of “refractory pain” and associated terms on the clinical decision to offer implantable therapies as well as argument for new definition. https://doi.org/10.1111/ner.12263.CrossRefPubMed

11.

Deer TR, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14(3):E283–312.PubMed

12.

Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol. 2010;8(2):52–9.PubMed

13.

•• Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, et al. The polyanalgesic consensus conference (pacc): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20(2):96–132. Expert consensus on practice guidelines for intrathecal therapies. https://doi.org/10.1111/ner.12538.CrossRefPubMed

14.

• Gulati A, Puttanniah V, Hung J, Malhotra V. Considerations for evaluating the use of intrathecal drug delivery in the oncologic patient. Curr Pain Headache Rep. 2014;18(2):391. Review of stepwise approach to implement implantable thearpies for cancer pain. https://doi.org/10.1007/s11916-013-0391-2.CrossRefPubMed

15.

•• Deer TR, Hayek SM, Pope JE, Lamer TJ, Hamza M, Grider JS, et al. The polyanalgesic consensus conference (pacc): recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20(2):133–54. Expert consensus on the trialing process for intrathetcal drug delivery prior to implantation. https://doi.org/10.1111/ner.12543.CrossRefPubMed

16.

Bruel BM, Burton AW. Intrathecal therapy for cancer-related pain. Pain Med. 2016;17:2404–21.

17.

•• Kurita GP, Benthien KS, Nordly M, Mercadante S, Klepstad P, Sjogren P. The evidence of neuraxial administration of analgesics for cancer-related pain: a systematic review. Acta Anaesthesiol Scand. 2015;59(9):1103–15. Excellent systematic review of existing evidence for intrathecal therapies for cancer pain with detailed tables listing findings and limitations of key studies. https://doi.org/10.1111/aas.12485.CrossRefPubMed

18.

Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–9. https://doi.org/10.1200/JCO.2002.02.118.CrossRefPubMed

19.

Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, et al. An implantable drug delivery system (idds) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (cmm). Ann Oncol. 2005;16(5):825–33. https://doi.org/10.1093/annonc/mdi156.CrossRefPubMed

20.

Sjoberg M, Appelgren L, Einarsson S, Hultman E, Linder LE, Nitescu P, et al. Long-term intrathecal morphine and bupivacaine in “refractory” cancer pain. I. Results from the first series of 52 patients. Acta Anaesthesiol Scand. 1991;35(1):30–43. https://doi.org/10.1111/j.1399-6576.1991.tb03237.x.CrossRefPubMed

21.

Sjoberg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology. 1994;80(2):284–97. https://doi.org/10.1097/00000542-199402000-00008.CrossRefPubMed

22.

Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, et al. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain. 2007;23(9):793–8. https://doi.org/10.1097/AJP.0b013e3181565d17.CrossRefPubMed

23.

• Mitchell A, McGhie J, Owen M, Mcginn G. Audit of intrathecal drug delivery for patients with difficult-to-control cancer pain shows a sustained reduction in pain severity scores over a 6-month period. Palliat Med. 2015;29(6):554–63. Positive prospective case series evaluating efficacy of intrathecal drug delivery in difficult to control cancer pain. https://doi.org/10.1177/0269216315570514.CrossRefPubMed

24.

Zheng S, He L, Yang X, Li X, Yang Z. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: a prospective cohort study. Medicine (Baltimore). 2017;96(11):e6354. https://doi.org/10.1097/MD.0000000000006354.CrossRef

25.

• Brogan SE, Winter NB, Okifuji A. Prospective observational study of patient-controlled intrathecal analgesia: impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction. Reg Anesth Pain Med. 2015;40(4):369–75. Positive prospective study evaluating the clinical response to patient-controlled intrathecal analgesia with respect to pain control and patient satisfaction in cancer pain. https://doi.org/10.1097/AAP.0000000000000251.CrossRefPubMed

26.

Liu HJ, Gao XZ, Liu XM, Xia M, Li WY, Jin Y. Effect of intrathecal dexmedetomidine on spinal morphine analgesia in patients with refractory cancer pain. J Palliat Med. 2014;17(7):837–40. https://doi.org/10.1089/jpm.2013.0544.CrossRefPubMed

27.

Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or aids: a randomized controlled trial. JAMA. 2004;291(1):63–70. https://doi.org/10.1001/jama.291.1.63.CrossRefPubMed

28.

Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag. 2006;31(5):393–406. https://doi.org/10.1016/j.jpainsymman.2005.10.003.CrossRef

29.

Dupoiron D, Bore F, Lefebvre-Kuntz D, Brenet O, Debourmont S, Dixmerias F, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician. 2012;15(5):395–403.PubMed

30.

Alicino I, Giglio M, Manca F, Bruno F, Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain. 2012;153(1):245–9. https://doi.org/10.1016/j.pain.2011.10.002.CrossRefPubMed

31.

• de la Calle Gil AB, Pena Vergara I, Cormane Bornacelly MA, Pajuelo Gallego A. Intrathecal ziconotide and morphine for pain relief: a case series of eight patients with refractory cancer pain, including five cases of neuropathic pain. Neurol Ther. 2015;4(2):159–68. Positive case series for the combination of morphine and ziconotide for cancer pain treatment. https://doi.org/10.1007/s40120-015-0035-z.CrossRefPubMedPubMedCentral

32.

Mamet J, Klukinov M, Yaksh TL, Malkmus SA, Williams S, Harris S, et al. Single intrathecal administration of the transcription factor decoy ayx1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury. Pain. 2014;155(2):322–33. https://doi.org/10.1016/j.pain.2013.10.015.CrossRefPubMed

33.

Brown DC, Agnello K, Iadarola MJ. Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain. Pain. 2015;156(6):1018–24. https://doi.org/10.1097/j.pain.0000000000000115.PubMedPubMedCentral

34.

•• Smyth C, Ahmadzai N, Wentzell J, Pardoe A, Tse A, Nguyen T, et al. Intrathecal analgesia for chronic refractory pain: current and future prospects. Drugs. 2015;75(17):1957–80. Excellent detailed review of intrathecal drug therapies and evidence behind use. https://doi.org/10.1007/s40265-015-0471-1.CrossRefPubMed

35.

Stearns LJ, Hinnenthal JA, Hammond K, Berryman E, Janjan NA. Health services utilization and payments in patients with cancer pain: a comparison of intrathecal drug delivery vs. conventional medical management. Neuromodulation. 2016;19(2):196–205. https://doi.org/10.1111/ner.12384.CrossRefPubMedPubMedCentral

36.

Brogan SE, Winter NB, Abiodun A, Safarpour R. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit. Pain Med. 2013;14(4):478–86. https://doi.org/10.1111/pme.12060.CrossRefPubMed

37.

Ottawa Hospital Research Institute, University of Ottawa, and Health Quality Ontario. Intrathecal drug delivery systems for cancer pain: a health technology assessment. Ont Health Technol Assess Ser [Internet]. 2016;16(1):1–51. Available from: http://www.hqontario.ca/evidence/publications-andohtac-recommendations/ontario-health-technology-assessment-series/hta-cancer-pain.

38.

Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015;6:CD009389.

39.

Shimoji K, Hokari T, Kano T, Tomita M, Kimura R, Watanabe S, et al. Management of intractable pain with percutaneous epidural spinal cord stimulation: differences in pain-relieving effects among diseases and sites of pain. Anesth Analg. 1993;77(1):110–6.CrossRefPubMed

40.

Yakovlev AE, Resch BE. Spinal cord stimulation for cancer-related low back pain. Am J Hosp Palliat Care. 2012;29(2):93–7. https://doi.org/10.1177/1049909111410414.CrossRefPubMed

41.

Yakovlev AE, Resch BE, Karasev SA. Treatment of cancer-related chest wall pain using spinal cord stimulation. Am J Hosp Palliat Care. 2010;27(8):552–6. https://doi.org/10.1177/1049909110373240.CrossRefPubMed

42.

Cata JP, Cordella JV, Burton AW, Hassenbusch SJ, Weng HR, Dougherty PM. Spinal cord stimulation relieves chemotherapy-induced pain: a clinical case report. J Pain Symptom Manag. 2004;27(1):72–8. https://doi.org/10.1016/j.jpainsymman.2003.05.007.CrossRef

43.

Clavo B, Robaina F, Montz R, Carames MA, Lloret M, Ponce P, et al. Modification of glucose metabolism in radiation-induced brain injury areas using cervical spinal cord stimulation. Acta Neurochir. 2009;151(11):1419–25. https://doi.org/10.1007/s00701-009-0400-8.CrossRefPubMed

44.

Lee MG, Choi SS, Lee MK, Kong MH, Lee IO, Oh HR. Thoracic spinal cord stimulation for neuropathic pain after spinal meningioma removal: a case report. Clin J Pain. 2009;25(2):167–9. https://doi.org/10.1097/AJP.0b013e3181839ad8.CrossRefPubMed

45.

Ting JC, Fukshansky M, Burton AW. Treatment of refractory ischemic pain from chemotherapy-induced Raynaud’s syndrome with spinal cord stimulation. Pain Pract. 2007;7(2):143–6. https://doi.org/10.1111/j.1533-2500.2007.00122.x.CrossRefPubMed

46.

Tsubota S, Higaki N, Nagaro T. A case of neuropathic cancer pain in the lower extremities successfully treated with spinal cord stimulation. Masui. 2009;58(11):1460–1.PubMed

47.

Yakovlev AE, Ellias Y. Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain. Clin Med Res. 2008;6(3–4):103–6. https://doi.org/10.3121/cmr.2008.813.CrossRefPubMedPubMedCentral

48.

Clavo B, Robaina F, Catala L, Perez JL, Lloret M, Carames MA, et al. Effect of cervical spinal cord stimulation on regional blood flow and oxygenation in advanced head and neck tumours. Ann Oncol. 2004;15(5):802–7. https://doi.org/10.1093/annonc/mdh189.CrossRefPubMed

Titel: Intrathecal Drug Delivery and Spinal Cord Stimulation for the Treatment of Cancer Pain
verfasst von: Fangfang Xing
R. Jason Yong
Alan David Kaye
Richard D. Urman
Publikationsdatum: 01.02.2018
Verlag: Springer US
Erschienen in: Current Pain and Headache Reports / Ausgabe 2/2018
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-018-0662-z

Neu im Fachgebiet AINS

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Intrathecal Drug Delivery and Spinal Cord Stimulation for the Treatment of Cancer Pain

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet AINS

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Hochrisiko-Eingriffe für postoperative Übelkeit

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

Update AINS

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Chronification of Pain: Mechanisms, Current Understanding, and Clinical Implications

The Effect of Ketamine Infusion in the Treatment of Complex Regional Pain Syndrome: a Systemic Review and Meta-analysis

Complex Regional Pain Syndrome, Current Concepts and Treatment Options

Pediatric Intracranial Hypertension: a Current Literature Review

Migraine and the Hippocampus

Neu im Fachgebiet AINS

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Hochrisiko-Eingriffe für postoperative Übelkeit

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

Update AINS